Read this company snapshot
Daily valuation snapshot
Sana Biotechnology, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $2.79
- Market capitalization (USD)
- $835,216,177.23
- Price / earnings (TTM)
- Not reported
- Price / book
- 5.4
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research SANA in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research SANA in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing SANA with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $2.79 |
| Market capitalization (USD) | $835,216,177.23 |
| Price / earnings (TTM) | Not reported |
| Price / book | 5.4 |
No matching rows. Clear the filter to see all records.
Read SANA's valuation metrics
Company size
Sana Biotechnology, Inc. Common Stock's recorded market capitalization is $835,216,177.23. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
SANA's recorded price-to-book ratio is 5.4. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Sana Biotechnology, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about SANA. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow SANA's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.